Triphenylchloroethylene

Triphenylchloroethylene
Clinical data
Trade namesGynosone, Oestrogyl
Other namesTPCE; Triphenylchlorethylene; Chlorotriphenylethylene; Phenylstilbene chloride
Drug classNonsteroidal estrogen
Identifiers
  • (1-chloro-2,2-diphenylethenyl)benzene
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H15Cl
Molar mass290.79 g·mol−1
3D model (JSmol)
  • C1=CC=C(C=C1)C(=C(C2=CC=CC=C2)Cl)C3=CC=CC=C3
  • InChI=1S/C20H15Cl/c21-20(18-14-8-3-9-15-18)19(16-10-4-1-5-11-16)17-12-6-2-7-13-17/h1-15H
  • Key:QEQFTTCZLHLKFX-UHFFFAOYSA-N

Triphenylchloroethylene (TPCE; brand names Gynosone, Oestrogyl), or triphenylchlorethylene, also known as chlorotriphenylethylene or as phenylstilbene chloride, is a synthetic nonsteroidal estrogen of the triphenylethylene group that was marketed in the 1940s for the treatment of menopausal symptoms, vaginal atrophy, lactation suppression, and all other estrogen-indicated conditions.[1][2][3]

The estrogenic effects of triphenylethylene, the parent compound of triphenylchloroethylene, were discovered in 1937.[4] Triphenylchloroethylene was first reported in 1938 and was found to have 20 to 100 times the estrogenic activity of the relatively weak triphenylethylene, a potentiation of effect that was afforded by its halogen substituent.[2][5] The drug has a relatively long duration of action when administered via subcutaneous injection but a duration similar to that of diethylstilbestrol or estradiol benzoate when administered orally.[2][6][7] Along with diethylstilbestrol and triphenylmethylethylene, triphenylchloroethylene was studied in 1944 by Sir Alexander Haddow for the treatment of breast cancer and was found to be significantly effective, and this is historically notable in that it was the first time that high-dose estrogens were found to be effective in the treatment of breast cancer.[8][9]

Chlorotrianisene, or tri-p-anisylchloroethylene (TACE), is a potent marketed estrogen and a derivative of triphenylchloroethylene in which each of the three phenyl rings has been substituted with a 4-methoxy group.[5][10] Estrobin, or DBE, is a related, never-marketed estrogen in which there is a bromine in place of the chlorine and two of the three phenyl rings have ethoxy groups.[5] Broparestrol, or BDPE is a marketed selective estrogen receptor modulator (SERM) that has a bromine in place of the chlorine of triphenylchloroethylene and a 4-ethyl group on one of the phenyl rings. The SERM clomifene is also a derivative of triphenylchloroethylene.[11]

See also

[edit]

References

[edit]
  1. ^ Negwer M, Scharnow HG (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. pp. 1861–1862. ISBN 978-3-527-30247-5. C20H15Cl 18084-97-4 Chlorotriphenylethene = Triphenylchloroethylene = Phenylstilbene chloride = 1,1',1"-(1-Chloro-1-ethenyl-2-ylidene)tris[benzene] (•) S Gynosone, Oestrogyl, Phenylstilbene chloride U Synthetic estrogen
  2. ^ a b c Emmens CW (July 1947). "Halogen-substituted oestrogens related to triphenylethylene". The Journal of Endocrinology. 5 (3): 170–173. doi:10.1677/joe.0.0050170. PMID 20259249.
  3. ^ ""Gynosone" A New Synthetic Oestrogen" (PDF). Advertisement. Proc R Soc Med. 39 (11). Sep 1946. PMC 2181944.
  4. ^ Li JJ (3 April 2009). "Genesis of Statins". Triumph of the Heart: The Story of Statins. Oxford University Press, USA. pp. 33–. ISBN 978-0-19-532357-3.
  5. ^ a b c Solmssen UV (December 1945). "Synthetic estrogens and the relation between their structure and their activity". Chemical Reviews. 37 (3): 481–598. doi:10.1021/cr60118a004. PMID 21013428.
  6. ^ Jordon VC, Koch R, Lieberman ME (1986). "Structure-Activity Relationships of Nonsteroidal Estrogens and Antiestrogens". In Jordan VC (ed.). Estrogen/antiestrogen Action and Breast Cancer Therapy. University of Wisconsin Press. pp. 23–. ISBN 978-0-299-10480-1.
  7. ^ Maximov PY, McDaniel RE, Jordan VC (23 July 2013). "Discovery and Pharmacology of Nonsteroidal Estrogens and Antiestrogens". Tamoxifen: Pioneering Medicine in Breast Cancer. Springer Science & Business Media. pp. 4–. ISBN 978-3-0348-0664-0.
  8. ^ Lewis-Wambi J, Jordan VC (27 May 2013). "Diethylstilbestrol: A Tragedy in Reproductive Endocrinology But a Pioneering Cancer Treatment". In Jordan VC (ed.). Estrogen Action, Selective Estrogen Receptor Modulators and Women's Health: Progress and Promise. World Scientific. pp. 42–. ISBN 978-1-84816-959-3.
  9. ^ Wagener DJ (13 July 2009). "The history of the hormonal treatment of cancer". The History of Oncology. Bohn Stafleu van Loghum. pp. 189–. ISBN 978-90-313-6143-4.
  10. ^ Lisi F (2006). "Adjunctions to Clomiphene Citrate". In Allahbadia G (ed.). Contemporary Perspectives on Assisted Reproductive Technology. Elsevier India. pp. 18–. ISBN 978-81-8147-782-8.
  11. ^ Shoham Z, Howles CM (27 June 2012). "Drugs used for ovarian stimulation: Clomiphene citrate, aromatase inhibitors, metformin, gonadotropins, gonadotropin-releasing hormone analogs and recombinant gonadotropins". In Gardner DK, Weissman A, Howles CM, Shoham Z (eds.). Textbook of Assisted Reproductive Techniques Fourth Edition: Volume 2: Clinical Perspectives. CRC Press. pp. 51–. ISBN 978-1-84184-972-0.
Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Triphenylchloroethylene&oldid=1187286863"